- Home
- APLT vs MNDO Comparison
APLT vs MNDO Comparison
Compare APLT & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- MNDO
- Stock Information
- Founded
- APLT 2016
- MNDO 1995
- Country
- APLT United States
- MNDO Israel
- Employees
- APLT N/A
- MNDO N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- MNDO EDP Services
- Sector
- APLT Health Care
- MNDO Technology
- Exchange
- APLT Nasdaq
- MNDO Nasdaq
- Market Cap
- APLT 37.5M
- MNDO 34.2M
- IPO Year
- APLT 2019
- MNDO 2000
- Fundamental
- Price
- APLT $0.40
- MNDO $1.39
- Analyst Decision
- APLT Buy
- MNDO
- Analyst Count
- APLT 7
- MNDO 0
- Target Price
- APLT $6.10
- MNDO N/A
- AVG Volume (30 Days)
- APLT 1.9M
- MNDO 51.2K
- Earning Date
- APLT 05-20-2025
- MNDO 05-06-2025
- Dividend Yield
- APLT N/A
- MNDO 16.00%
- EPS Growth
- APLT N/A
- MNDO N/A
- EPS
- APLT N/A
- MNDO 0.17
- Revenue
- APLT $455,000.00
- MNDO $20,677,000.00
- Revenue This Year
- APLT $1,768.13
- MNDO N/A
- Revenue Next Year
- APLT $361.28
- MNDO N/A
- P/E Ratio
- APLT N/A
- MNDO $8.53
- Revenue Growth
- APLT N/A
- MNDO N/A
- 52 Week Low
- APLT $0.30
- MNDO $1.43
- 52 Week High
- APLT $10.62
- MNDO $2.13
- Technical
- Relative Strength Index (RSI)
- APLT 46.92
- MNDO 16.01
- Support Level
- APLT $0.39
- MNDO $1.66
- Resistance Level
- APLT $0.44
- MNDO $1.69
- Average True Range (ATR)
- APLT 0.04
- MNDO 0.04
- MACD
- APLT 0.01
- MNDO -0.02
- Stochastic Oscillator
- APLT 45.49
- MNDO 12.86
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.